Researcher sitting at his lab desk working

ViiV Scientific Data at CROI 2021

At the 28th edition of the Conference on Human Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented amongst others, abstracts around some of the latest findings and progress being made on HIV/AIDS research.

ViiV Abstracts for CROI 2021

 

Abstract title

Inflammatory and atherogenesis markers 148 weeks post-switch to DTG + RPV in SWORD-1/-2

Science Spotlight

Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) through 96 weeks: subgroup analyses from the TANGO study

Science Spotlight

Durable efficacy of DTG + 3TC in GEMINI-1&-2: year 3 subgroup analyses

Science Spotlight

Association between newer antiretrovirals and increase in body mass index in RESPOND

Science Spotlight
Association between integrase inhibitors (INSTIs) and cardiovascular disease Science Spotlight

Cabotegravir PPK simulation to inform Q2M strategies following dosing interruptions

Science Spotlight

Weight and lipid changes in phase 3 cabotegravir and rilpivirine long-acting trials

Science Spotlight

Long-acting cabotegravir + rilpivirine in older adults: pooled phase 3 Week 48 results

Science Spotlight
Week 96 efficacy and safety of cabotegravir + rilpivirine every 2 months: ATLAS-2M Science Spotlight

Renal/bone outcomes after long-acting cabotegravir + rilpivirine in ATLAS + ATLAS-2M

Science Spotlight

PopPK modeling of Q2M IM RPV LA for managing dosing interruptions in HIV-1 patients

Science Spotlight

Reduced susceptibility to temsavir is not linked to IBA or MVC resistance

Science Spotlight
Randomised Controlled Trial (RCT) of an online mental health intervention among older PLWH during COVID-19 pandemic Oral Presentation

Follow us on 

and use the official hashtags #CROI2021 and #WeWontStop.